Liproxstatin-1 [950455-15-9]
Cat# NB-64-13035-5mg
Size : 5mg
Brand : Neo Biotech
Contact local distributor :
Phone : +1 850 650 7790
Remove All
Liproxstatin-1
Copy Product InfoSynonyms:
Catalog No. T2376 Copy Product Info
Purity: 99.72%
Liproxstatin-1 is a potent and selective inhibitor of ferroptosis (IC50=22 nM). Liproxstatin-1 protects cells from ferroptosis induced by ferroptosis inducers (e.g., Erastin, RSL3).
Cas No. 950455-15-9
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.72%
Contact us for more batch information
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Liproxstatin-1 is a potent and selective inhibitor of ferroptosis (IC50=22 nM). Liproxstatin-1 protects cells from ferroptosis induced by ferroptosis inducers (e.g., Erastin, RSL3). |
| Targets & IC50 | Fibroblast:22 nM (EC50), Lymphocyte:22 nM (EC50), Ferroptosis:22 nM |
| In vitro | METHODS: Mouse fibroblasts L929 were treated with Liproxstatin-1 (0-250 nM) for 24 h. Cell viability was measured using AquaBluer. RESULTS: Liproxstatin-1 protected against FINs such as BSO (10 μM), erastin (1 μM), and RSL3 (0.5 μM) in a dose-dependent manner, while it did not rescue staurosporine (0.2 μM) or H2O2 (200 μM)-induced cell death. [1] METHODS: Oligodendrocytes OLN93 were treated with Liproxstatin-1 (1 μM) and RSL-3 (7.89 μM) for 24 h, and GSH levels were measured by micro reduced GSH assay kit. RESULTS: Liproxstatin-1 treatment increased GSH levels compared to the RSL-3 group. [2] |
| In vivo | METHODS: To test the potential to prevent animal-induced Gpx4 destruction in vivo, Liproxstatin-1 (10 mg/kg) was administered intraperitoneally to TAM-treated CreERT2;Gpx4fl/fl mice once daily for two weeks. RESULTS: Liproxstatin-1 significantly prolonged survival. the number of TUNEL+ cells in the Liproxstatin-1 group was significantly reduced, and the table Liproxstatin-1 delayed the desmoplasia of renal tubular cells. [1] METHODS: To investigate the role of ferroptosis in inflammation-associated cognitive deficits, Liproxstatin-1 (10 mg/kg) was administered intraperitoneally to C57BL/6 mice once daily for five days followed by LPS administration. RESULTS: Liproxstatin-1 ameliorated memory deficits in a mouse model of LPS-induced cognitive impairment.The protective effects of Liproxstatin-1 were associated with attenuation of iron deposition and modulation of the iron-death-associated protein families, TF, xCT, Fth, Gpx4 and FtMt. [3] |
| Cell Research | Cell viability is assessed at different time points after treatment using AquaBluer according to the manufacturer’s recommendations. Alternatively, cell death is also quantified by measuring released lactate dehydrogenase activity using the cytotoxicity detection kit (LDH). (Only for Reference) |
| Molecular Weight | 340.85 |
| Formula | C19H21ClN4 |
| Cas No. | 950455-15-9 |
| Smiles | Clc1cccc(CNC2=Nc3ccccc3NC22CCNCC2)c1 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||
| Solubility Information | Ethanol: soluble H2O: Insoluble DMSO: 255 mg/mL (748.13 mM), Sonication is recommended.  | ||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 6 mg/mL (17.6 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||